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Abstract
Background: In Côte d’Ivoire during 2004–2007, numbers of ART enrollees increased from ,5,000 to 36,943. Trends in
nationally representative ART program outcomes have not yet been reported.
Methodology/Principal Findings: We conducted a retrospective chart review to assess trends in patient characteristics and
attrition [death or loss to follow-up (LTFU)] over time, among a nationally representative sample of 3,682 adults ($15 years)
initiating ART during 2004–2007 at 34 health facilities. Among ART enrollees during 2004–2007, median age was 36, the
proportion female was 67%, the proportion HIV-2-infected or dually HIV-1&2 reactive was 5%, and median baseline CD4+ T-
cell (CD4) count was 135 cells/mL. Comparing cohorts initiating ART in 2004 with cohorts initiating ART in 2007, median
baseline weight declined from 55 kg to 52 kg (p = 0.008) and the proportion weighing ,45 kg increased from 17% to 22%
(p = 0.014). During 2004–2007, pharmacy-based estimates of the percentage of new ART enrollees $95% adherent to ART
declined from 74% to 60% (p = 0.026), and twelve-month retention declined from 86% to 69%, due to increases in 12-month
mortality from 2%–4% and LTFU from 12%–28%. In univariate analysis, year of ART initiation was associated with increasing
rates of both LTFU and mortality. Controlling for baseline CD4, weight, adherence, and other risk factors, year of ART
initiation was still strongly associated with LTFU but not mortality. In multivariate analysis, weight ,45 kg and adherence ,
95% remained strong predictors of LTFU and mortality.
Conclusions: During 2004–2007, increasing prevalence among ART enrollees of measured mortality risk factors, including
weight ,45 kg and ART adherence ,95%, might explain increases in mortality over time. However, the association
between later calendar year and increasing LTFU is not explained by risk factors evaluated in this analysis. Undocumented
transfers, political instability, and patient dissatisfaction with crowded facilities might explain increasing LTFU.
Citation: Auld AF, Ekra KA, Shiraishi RW, Tuho MZ, Kouakou JS, et al. (2014) Temporal Trends in Treatment Outcomes for HIV-1 and HIV-2-Infected Adults Enrolled
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Introduction
Similar to other countries in West Africa [1,2], Côte d’Ivoire
faces a dual epidemic of HIV-1 and HIV-2 [3]. Current adult
HIV-1 prevalence is estimated at 3% [4], while about 5% of HIV-
infected adults are HIV-2 or HIV-1&2 dually reactive [5].
Although the burden of the HIV-2 epidemic is limited [1,6],
antiretroviral therapy (ART) programs need to provide supplies
and training for adequate identification and treatment of HIV-2,
which differs from that of HIV-1 [7], complicating the program in
an already challenging setting [8], where resources are limited and
political instability has culminated in two civil wars in the last
decade [9].
Despite these challenges, the Ministry of Health (MOH) and
international partners, including the United States (U.S) Presi-
dent’s Emergency Plan for Relief (PEPFAR) and the Global Fund
to Fight AIDS, Tuberculosis, and Malaria (GFATM), have
increased numbers of ART enrollees about 20-fold from less than
5,000 to 104,750 during 2004–2012 [10]. Although sub-national
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ART programs in Côte d’Ivoire have reported their treatment
experience for the period 2004–2008 [5,11], these previous reports
cannot be considered nationally representative [12,13]. Investi-
gating and reporting national ART program outcomes is
important to provide a representative assessment of program
quality and justify continued funding [14–16]. Describing program
trends over time at a national level, and assessment of factors
associated with national outcomes, can help to identify areas for
national program improvement activities [17,18].
Therefore, in 2009–2010, we conducted a retrospective, cohort
study among a nationally representative sample of adult ART
patients starting ART during 2004–2007, to describe trends in
patient characteristics at ART initiation over time and trends in
mortality and loss to follow-up (LTFU).
Methods
Ethics Approval
This study was approved by the Ivorian Ethics Review
Committee (Comité National d’Éthique des Sciences de la Vie et de la
Santé), the Institutional Review Board (IRB) of the U.S. Centers for
Disease Control and Prevention (CDC), and the Harvard School
of Public Health IRB. Patient informed consent was not required
as only routine, anonymized, monitoring data were collected and
analyzed.
Eligibility for ART
During 2004–2007, patients were eligible for ART when
diagnosed as having World Health Organization (WHO) stage
IV, WHO stage III with CD4 counts #350/mL, or WHO stage I/
II with CD4 counts #200/mL [5]. Prescription of co-trimoxazole
(CTX) was indicated for all ART patients with CD4 count #350/
mL.
For HIV-1-infected patients, recommended first-line ART
regimens included stavudine (D4T) or zidovudine (AZT) with
lamivudine (3TC) and either nevirapine (NVP) or efavirenz (EFV)
or, a triple nucleoside reverse transcriptase inhibitor (NRTI)
regimen of AZT, 3TC and abacavir (ABC), if one of the non-
nucleoside reverse transcriptase inhibitors (NNRTIs) was contra-
indicated. For HIV-2-infected or dually reactive patients, recom-
mended first-line therapy was D4T or AZT with 3TC and
ritonavir-boosted indinavir (IND/r).
Patient Monitoring
At ART initiation, monthly for the first 3 months, and quarterly
thereafter, standardized MOH-recommended medical records
were completed to monitor disease progression or improvement.
Patients collected medications monthly from clinic pharmacies
where the date of scheduled antiretroviral (ARV) pick-up
appointments and actual ARV pick-updates were documented.
Study Design and Population
This was a retrospective cohort study. Patient-level data were
abstracted from standardized, MOH-recommended medical
records onto study questionnaires by trained abstractors from
November 2009 through March 2010. Only medical records of
adult patients, $15 years old at ART initiation, who started ART
during 2004–2007, were eligible.
Sample Size
Sample size calculations were performed using Epi Info software
(CDC, Epi Info 2008, Version 3.5.1, Atlanta, GA). To achieve a
95% confidence interval (CI) of +2.5% around the estimate for 12-
month attrition, assuming a design effect of 1.5 [13], and a
conservative (i.e., higher than expected) 12-month attrition
percentage of 50% [19], a sample size of $2,301 patient records
was needed. To meet the needs of a secondary analysis, aimed at
assessing site-level predictors of patient outcomes, we aimed to
sample 4,000 medical records.
Sampling
Of 124 ART delivery sites in the country by December 31,
2007, 78 had provided ART to $50 adults. Only 833 (2.3%) of all
36,943 adult patients who had received ART by December 31,
2007, were enrolled at sites that had supported ,50 patients on
ART by this time. To maintain feasibility, 35 (45%) of the 78
eligible sites were randomly selected, using a two-stage sampling
strategy. In stage one, the 78 eligible clinics were divided into three
strata based on which organization was largely responsible for
implementing the ART program at the site (non-governmental
organization, MOH, or GFATM through MOH). Within these
three strata, sub-strata were created according to site size (number
of ART patients ever enrolled). Site size sub-strata were: small (50–
250), medium (251–1,000), and large (.1,000). Within each
substratum, SAS 9.2 (SAS Institute Inc., Cary, NC) was used to
randomly sample facilities using probability-proportional-to-size
sampling. Of the selected 35 clinics, 34 agreed to participate.
In stage two, simple random sampling was used to select 4,000
medical records from the 34 selected, consenting facilities. The
total number of medical records selected in each sub-stratum was
proportional to the number of eligible records in the correspond-
ing sub-stratum in the general adult ART population by 2007.
Treatment Outcomes
The primary outcomes of interest after ART initiation were
documented death and LTFU, and the secondary outcome of
interest was the composite outcome of attrition (documented death
or LTFU). A patient was considered LTFU if he/she was absent
from the health facility in the 90 days preceding data abstraction,
and if there was no documentation of death or transferal to
another health facility. The date of LTFU was recorded as the
date of the most recent visit. Transfers were censored from time-
to-event analyses at the date of transfer. Data for time-to-event
analysis (i.e. date of ART initiation and date and nature of the
final outcome status) were complete.
Exposure Variables
Patient-level characteristics routinely captured on standard
MOH medical records (Table 1) were considered a priori risk
factors for inclusion in the multivariable models for each of the
three outcomes — death, LTFU, and overall attrition. CD4 count
and hemoglobin categories [20,21] and weight categories [22]
were chosen based on published precedent. Suitability of the ART
regimen was assigned according to published international
guidelines [7,23]. ART adherence during months 0–6 of ART
was estimated by timeliness to drug pick-up appointments (i.e.,
every day late for a pharmacy drug pick-up appointment during
months 0–6 of ART was equivalent to one missed day of ART
doses) [24–26]. Only site size was included as a site-level variable
in this analysis [5,12].
Analytic Methods
Data were analyzed using SAS 9.2 (SAS Institute Inc., Cary,
NC), and STATA 11 (StataCorp, 2009, Stata Statistical Software,
Release 11, College Station, TX). The anonymized dataset is
available upon request from the analysis working group, compris-
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ing the corresponding author, members of the MOH, CDC, and
the Elizabeth Glaser Pediatric AIDS Foundation.
Missing data, reported for each baseline covariate of interest in
Table 1, were assumed to be missing at random (MAR), and were
imputed using multiple imputation with chained equations [27].
The ice [28–30] procedure in STATA was used to create 20
imputed datasets for each of the following outcomes: (1)
documented death, (3) LTFU, and (3) overall attrition [13]. The
imputation model included the event indicator, all study variables,
and the Nelson-Aalen estimate of cumulative hazard [31]. For all
analyses using imputed data, estimates were combined across the
imputed datasets according to Rubin’s rules [27] using the mim
procedure in STATA [32].
To assess the association between baseline characteristics and
year of ART initiation, linear, logistic, ordered, or multinomial
logistic regression models, accounting for study design, were used
for continuous, binary, ordinal, and nominal categorical variables,
respectively. To assess the association between baseline charac-
teristics and sex, unadjusted logistic regression, accounting for
study design, was used.
A competing risks model was used to estimate 6-, 12-, and 24-
month mortality and LTFU for each annual cohort of adults
starting ART during 2004–2007 [33]. Stacked cumulative
incidence curves were used to illustrate cumulative probability of
death and LTFU over time for each annual cohort of adults
starting ART [33].
In time-to-event analysis, Cox proportional hazards regression
models that controlled for study design were used to estimate
crude and adjusted hazard ratios (AHR) and 95% confidence
intervals (CI) for covariates of interest [34]. The proportional
hazards assumption was assessed using visual methods and the
Grambsch and Therneau test [35]. Kaplan-Meier curves were
used to examine cumulative probability of retention (1-attrition)
over time stratified by baseline variables.
Results
Trends in Patient Characteristics at ART Initiation
Data from medical records of 3,682 eligible, adult ART patients
were abstracted and analyzed. Year of ART enrollment for adult
ART patients included in the study was 2004, 2005, 2006, and
2007, for 6%, 22%, 36% and 36%, respectively. During 2004–
2007, 67% of patients were female, median age was 36 years, most
patients (95%) were HIV-1-infected, 2% were HIV-2-infected,
and 3% were HIV-1&2 dually reactive. These variables did not
change significantly over time.
Overall, 59% of patients reported employment, but the
proportion reporting employment declined from 65% to 56%
during 2004–2007 (p = 0.027). Most patients had WHO stage III
(58%) or IV (22%) with no significant changes over time (Table 1).
Median ART enrollment weight was 53 kg, but declined from
55 kg to 52 kg during 2004–2007 (p = 0.008). Similarly, the
proportion with very low weight (,45 kg) at ART initiation was
20% overall, but increased from 17% to 22% during 2004–2007
(p = 0.014). During 2004–2007, the proportion with hemoglobin
,8 g/dL was 14% and this did not change over time. Median
CD4 count overall was 135 cells/mL and did not change
significantly over time (p = 0.363).
The proportion of patients prescribed CTX at ART initiation
was 59% and this did not change significantly over time. The
proportion achieving 95% adherence to pharmacy pick-up
appointments decreased from 74% to 60% during 2004–2007
(p = 0.026). The proportion of patients prescribed sub-optimal
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(p = 0.245). The proportion of patients enrolling at smaller sites
(sites with #1,000 enrollees) increased from 12% to 64%
(p = 0.001) during 2004–2007.
Gender Differences
Compared with females at ART enrollment, males had a higher
median age (40 vs. 34, p,0.001), a higher prevalence of HIV-2 or
dual HIV-1&2 reactivity (8% vs. 4%, p,0.001), and were more
likely to report employment (82% vs. 47%, p,0.001). Compared
with female ART enrollees, males had a higher median weight
(57 kg vs. 50 kg, p,0.001) and a lower prevalence of severe
anemia (HB ,8 g/dL) (10% vs. 16%, p,0.001), but also a lower
median CD4 count (119/mL vs. 146/mL, p,0.001). Adherence to
ART ,95% was not significantly different between males (33%)
and females (35%, p = 0.553).
ART Regimen Prescription
Eighty-four different initial ART regimens were prescribed to
ART enrollees during 2004–2007 (Table 2). Across all patients,
D4T+3TC+NVP (44%) and D4T+3TC+EFV (23%), were the
most common regimens prescribed.
Among 182 HIV-2-infected or dually reactive adults, optimal
first-line therapy of two NRTIs and a boosted PI were prescribed
to 41% of patients. Sub-optimal regimens were prescribed to the
remaining 56% of HIV-2-infected or dually reactive adults: two
NRTIs with an NNRTI were prescribed to 25%, triple NRTIs to
11%, two NRTIs with an unboosted PI to 10%, and monotherapy
to 6% (Table 2).
Overall, 283 (8%) of all patients were prescribed sub-optimal
regimens (Table 2). Sub-optimal ART regimen prescription was
more common for HIV-2-infected or dually reactive patients
compared with HIV-1-infected patients (56% vs. 5%, p,0.001).
Treatment Outcomes
Among 3,682 enrollees, 1,778 (49%) were alive on ART at the
same facility by the time of data abstraction, 1,481 (40%) became
LTFU, 216 (7%) died, and 207 (6%) had been transferred out to
another facility. At 6, 12, 24, 36, 48, and 60 months after ART
initiation, ART retention was 79%, 74%, 65%, 56%, 48%, and
46% respectively.
During 2004–2007, 12-month retention declined from 86% for
2004 ART enrollees, to 82% for 2005, 73% for 2006, and 69% for
2007 enrollees (Table 3, Figure 1). Declines in 12-month retention
were due to increases in 12-month mortality from 2% to 4%, and
LTFU from 12% to 28% for 2004 compared with 2007 enrollees.
Similarly, rates of mortality increased from 1.5/100 person-years
(PY) for 2004 enrollees to 3.9/100 PY for 2007 enrollees, while
rates of LTFU increased from 9.2/100 PY for 2004 enrollees to
28.1/100 PY for 2007 enrollees (Table 4). Rates of overall attrition
Table 3. Incidence of Death and Lost to Follow-up among Adult ART Enrollees in Côte d’Ivoire during 2004–2007 by Calendar Year
of ART Initiation*.
Years After ART Initiation 2004 2005 2006 2007
Death 0.5 1.3% 3.1% 4.7% 3.4%
1 1.8% 4.0% 5.4% 3.9%
2 3.4% 4.8% 6.8% 5.6%
3 4.0% 5.7% 8.0% 7.0%
4 4.2% 7.1% 8.2% 7.0%
LTFU 0.5 10.3% 10.3% 17.5% 22.6%
1 12.1% 14.1% 21.2% 27.6%
2 16.5% 19.8% 27.5% 39.5%
3 21.4% 24.1% 37.6% 49.0%
4 26.6% 32.9% 50.4% 49.0%
Attrition** 0.5 11.6% 13.4% 22.2% 26.1%
1 13.9% 18.1% 26.6% 31.5%
2 20.0% 24.5% 34.3% 45.1%
3 25.3% 29.9% 45.6% 56.0%
4 30.8% 40.0% 58.6% 56.0%
Retention** 0.5 88.4% 86.6% 77.8% 73.9%
(1-attrition) 1 86.1% 81.9% 73.4% 68.5%
2 80.0% 75.5% 65.7% 54.9%
3 74.7% 70.1% 54.4% 44.0%
4 69.2% 60.0% 41.4% 44.0%
Abbreviations: LTFU, loss to follow-up; ART, antiretroviral therapy.
*Incidence estimates were derived from a competing risks analysis.
**Attrition is defined as the proportion of patients who have died or been loss to follow-up. Retention is defined as (1-attrition). Transfer outs were censored at the time
of transfer.
doi:10.1371/journal.pone.0098183.t003
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increased from 10.7/100 PY for 2004 enrollees to 32.0/100 PY for
2007 enrollees (Table 5).
Predictors of Outcomes
A 10-year increase in age at ART initiation was associated with
an 11% reduction in LTFU risk (AHR 0.89; 95% CI, 0.83–0.96)
but not mortality risk (Table 4). Male sex was borderline predictive
of mortality (AHR 1.65; 95% CI, 0.98–2.76, p = 0.058) and was
associated with LTFU (AHR 1.57; 95% CI, 1.31–1.89). HIV type
was not associated with mortality or LTFU risk.
Compared with WHO stage I/II, WHO stage IV was
predictive of mortality (AHR 3.07; 95% CI, 1.22–7.72), but not
LTFU (Table 4). Compared with having a weight .60 kg, having
a weight ,45 kg was predictive of mortality (AHR 2.05; 95% CI,
1.22–3.46), and LTFU (AHR 1.90; 95% CI, 1.49–2.41).
Compared with having a CD4.350 cells/mL at ART initiation,
having a CD4,50 cells/mL was predictive of mortality (AHR
3.00; 95% CI, 1.13–7.95), but not LTFU.
Failure to prescribe CTX was associated with increased risk of
LTFU (AHR 1.40; 95% CI, 1.12–1.75), but not documented
mortality (Table 4).
Adherence to ART drug refill appointments ,95% was
associated with borderline increased mortality (AHR 2.08, 95%
CI, 0.97–4.46, p = 0.058) and increased LTFU risk (AHR 1.51,
95% CI, 1.12–2.03).
In crude analysis, enrollment at smaller sites (,1,000 enrollees)
was predictive of mortality, but this was not significant in
multivariable analysis.
In crude analysis, year of ART enrollment was associated with
both mortality and LTFU (Table 4). However, in adjusted
analysis, year of enrollment was only associated with increasing
LTFU rates and not mortality (Table 4).
Factors predictive of overall attrition in adjusted analysis
included younger age, male sex (Figure 2A), very low weight
(Figure 2B), CD4 count ,50 cells/mL, failure to prescribe CTX at
ART initiation, adherence to ART ,95% (Figure 2C), and later
calendar year of ART initiation (Figure 2 D, Table 5).
Discussion
This is the first nationally representative evaluation of Côte
d’Ivoire’s adult ART program, and the first to evaluate trends in
program outcomes over time, and has several important findings.
Declining ART Retention over Time
The most concerning finding of our analysis is the decrease in
12-month retention from 86% for 2004 ART enrollees to 69% for
Figure 1. Cumulative Incidence of Mortality and Loss to Follow-up (LTFU) among Adults Enrolled in Côte d’Ivoire’s National ART
Program during 2004–2007.
doi:10.1371/journal.pone.0098183.g001
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ART Outcomes in Adults - Côte d’Ivoire
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2007 enrollees. Compared with average 12-month retention for
African ART programs during 2004–2007 (75-80% [19,36]), 12-
month retention for ART enrollees in 2006 (72%) and 2007 (69%),
was low.
The declining 12-month retention estimates are due to nearly
three-fold increases in rates of LTFU (from 9.2–28.1/100 PY), and
documented mortality (from 1.5–3.9/100 PY). While year of ART
initiation was associated with both mortality and LTFU in
unadjusted analysis, in multivariable analysis, controlling for other
known predictors of death and LTFU, ART initiation year was
only associated with LTFU.
The likely explanation for this finding is that other measured
mortality risk factors were confounding the crude association
between ART initiation year and mortality. Both prevalence of
very low weight at ART initiation and non-adherence to ART in
months 0-6 of ART, increased among successive annual cohorts of
ART enrollees, and were associated with mortality. In contrast,
measured risk factors for LTFU in this study do not explain the
association between year of ART initiation and LTFU. This
analysis has important implications for the program response to
declining retention.
Program Response to Increasing Mortality
Addressing increasing prevalence of sub-optimal nutritional
status and declining ART adherence may help program managers
to reverse trends of increasing mortality rates. Increasing
prevalence of nutritional insufficiency may be related to increasing
food insecurity [37], which may be related to increasing political
instability since the late 1990s that culminated in the second
Ivorian civil war in 2011 [9]. Alternately, expansion of the ART
program to more rural areas, especially in the north of the
country, where food insecurity is more common [37], might
explain the worsening baseline nutritional status of ART enrollees.
The increasing proportion of ART enrollees who report being
unemployed (from 31% to 42% during 2004–2007) supports the
theory that food insecurity might underpin increasing prevalence
of sub-optimal nutritional status. In Côte d’Ivoire, where 23% of
the population live on ,$1.23/day [38], further research to
evaluate the health benefits of integrated nutrition programs in
adult ART clinics might be warranted [39–41].
Addressing food insecurity, for example through clinic-based
food assistance [39–41], may also help to address the problem of
declining ART adherence [39]. Other interventions to improve
adherence might include targeting patients who display sub-
optimal pharmacy-based measures of adherence during months 0-
6 of ART, with a package of adherence interventions including
viral load testing [42,43]; this targeted approach might improve
adherence [43], reduce mortality [44], and reduce LTFU risk
[11].
Figure 2. Kaplan-Meier Curves Showing Retention among Adults Initiating ART in Côte d’Ivoire during 2004–2007 Stratified by Risk
Factors for Attrition.
doi:10.1371/journal.pone.0098183.g002
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Program Response to Increasing LTFU
Identifying the causes of increasing LTFU rates in future studies
is important to allow identification of possible interventions.
Increasing rates of LTFU have been documented in other
countries with rapidly expanding ART programs, including South
Africa [45,46] and Mozambique [13]. Two factors may be
contributing to increasing LTFU: firstly, with increasing patient
load, attention to timely, accurate maintenance of medical records
may be compromised, resulting in missing entries for clinic visits or
undocumented transfers [46,47]. Developing and implementing
effective electronic monitoring systems, with dedicated data
management personnel, could improve data quality and accuracy
[47].
Secondly, with increasing patient-to-provider ratios, patient
waiting times are increased, and waiting rooms become more
crowded [45,48–50]. This may be associated with patient and
clinician dissatisfaction with clinic conditions, which may be one
cause for increasing LTFU [51–55]. Reducing patient-to-provider
ratios might be facilitated by several interventions including
increasing the workforce, task shifting [56], or decreasing visit
frequency for stable patients [57]. One method to decrease visit
frequency for stable patients is formation of community adherence
support groups (CASG). CASGs comprise groups of 6–10 patients,
who take turns to collect the group’s ART medications from clinic
pharmacies each month. In Mozambique a pilot project signifi-
cantly reduced 12-month LTFU [58]. Alternately, distribution of
ART at locations closer to patient’s homes might reduce patient
and clinic burden and might improve retention [59].
Co-trimoxazole for ART Enrollees
In our study, failure to prescribe CTX to ART enrollees was
associated with increased LTFU and overall attrition. It is unclear
whether CTX reduced morbidity, which contributed to reductions
in LTFU [60,61], or whether clinician compliance with CTX
prescription was a marker of higher quality clinical care.
Regardless, there is considerable evidence [13,60,61] supporting
the need to prescribe CTX to all ART enrollees.
Male Gender
As has been documented in other African cohorts
[5,13,20,22,62], males had a lower baseline median CD4 count
than females, a higher risk of LTFU, and marginally increased
mortality. Delayed presentation for care might be due to gender
norms, which discourage men from admitting ill-health, while
higher rates of LTFU might reflect differences in adherence to
chronic care [13,62,63]. However, higher background mortality
among men in general, regardless of HIV status, might explain
gender differences in mortality during ART follow-up [62]. In
Côte d’Ivoire’s general population, mortality is higher among
males than females (472 deaths/1,000 men vs. 385 deaths/1,000
women) [64]. Increased male mortality is attributed to accidents,
homicide, suicide [65], and increased opportunistic infections
[62,65,66]. In our cohort, higher male LTFU may also be due to
underlying increased mortality [22], a proportion of which goes
undocumented [67]. However, further research is needed to
inform intervention strategies.
Younger Age
In our study, as in others [13,46], younger age was predictive of
LTFU risk. Point estimates of LTFU rates were higher in
adolescents (aged 15-,20 years at ART initiation) at 19.5/100
PY and young adults (aged 20-,25) at 24.4/100 PY, compared
with adults aged 25-,75 at ART initiation (range: 0-18.7/100
PY). This may be because younger people are more mobile. In
west Africa, migration for work is particularly common among
adults in their twenties and thirties, especially among men [68].
Increased risk for LTFU among adolescents has been documented
in other studies [69]. Possible cognitive impairment among
perinatally infected children who start ART late as adolescents,
lack of youth-friendly services, rigid scheduling, increasing
responsibilities, and decreasing involvement of adult caregivers
all contribute to the challenge of retaining adolescents and young
adults on ART [69]. Youth-specific retention interventions may be
needed to keep young adults on ART in Côte d’Ivoire.
HIV-2 and Dual HIV-1&2 Reactivity
As in other countries [8], HIV-2 and dual reactivity were poorly
managed, with 56% of affected patients prescribed sub-optimal
first-line regimens. Similar to Burkina Faso [8], 25% of HIV-2-
infected or dually reactive patients were prescribed NNRTI-
containing regimens, to which HIV-2 is resistant [70–72]. A
further 11% of patients were prescribed two NRTIs with an
unboosted PI, which has been associated with poor treatment
outcomes in Côte d’Ivoire [73] and Senegal [7,74]. Triple NRTI
therapy is also not recommended [7], due to poor outcomes
[75,76], and risk of Q151M pan-NRTI resistance [77]. Similarly,
mono- and dual-therapy are associated with resistance and poor
outcomes [7]. Possible reasons for poor HIV-2 management
include insufficient training of clinicians, and low availability of
ritonavir-boosted regimens, either due to stock outs [78], or lack of
a cold chain prior to availability of heat-stable lopinavir-ritonavir
[7]. Clinician training and drug supply and demand issues are
being addressed [78].
Limitations
Firstly, these analyses rely on routinely collected and sometimes
incomplete data. Missing data on baseline patient characteristics
likely introduced non-differential measurement error. Given the
proportion of data missing for the adherence variable, prevalence
of non-adherence and hazard ratios associated with non-adher-
ence should be viewed with caution, although findings are in line
with other publications from Côte d’Ivoire [11,39]. Secondly, our
reported LTFU rate is likely an over-estimate due to the
probability of undocumented death [67] or undocumented
transfer [47] being observed as LTFU. Similarly, our reported
mortality rate is likely an underestimate of true mortality [67].
Finally, these data show trends for patients enrolled during 2004–
2007 and trends may have changed in more recent years.
Conclusions
Increased prevalence of sub-optimal nutritional status and sub-
optimal ART adherence, might explain increases in documented
mortality over time. Earlier ART initiation before nutritional
compromise and targeted adherence interventions might help
reverse trends of increasing mortality. Further research to assess
the survival benefit of food supplementation for food-insecure
ART enrollees, might be warranted. Increasing LTFU rates are
not explained by risk factors analyzed in this report. Undocu-
mented transfers, political instability, or patient dissatisfaction with
crowded facilities might explain increasing LTFU. Implementing
electronic monitoring systems to improve data quality, and
innovative LTFU-prevention strategies, possibly targeting men
and younger patients, might reverse trends of increasing LTFU.
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